First-in-Human Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects

Trial Profile

First-in-Human Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs ABT 122 (Primary) ; ABT 122 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Jul 2017 Results of pooled analysis from three phase I studies including this study published in the Clinical Pharmacokinetics
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2015 Results presented (pooled analysis of 3 phase I trials) at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top